Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Kabi, is a 5‑HT3 receptor antagonist presented as an intravenous solution for injection use. It treats and helps prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways related to several medical situations. - Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: Helps control the onset of nausea during and after radiation treatment. - Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea and vomiting after surgical procedures.

Side effects reported with intravenous ondansetron are generally mild to moderate and vary with individual tolerance.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional reduced bowel movements. - Fatigue: feeling of tiredness or low energy. - Dizziness: transient light‑headedness. - Injection site reactions: mild erythema or discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythms. - Severe hypersensitivity: anaphylaxis, angio‑edema, or skin rash. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Neuro‑muscular weakness: rare cases of muscle tone reduction.

When using Ondansetron Kabi, clinicians should consider several safety aspects before and during therapy. - Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should have ECG monitoring. - Concomitant serotonergic drugs: avoid or closely monitor use with other agents that increase serotonin levels. - Pregnancy and lactation: assess risk‑benefit ratio; limited data suggest caution. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgement. - Drug interactions: review patient medication list for potential interactions. Store at ambient temperature: keep in original packaging, protect from light and moisture.

Store at ambient temperature: keep the vial in the original packaging and protect from light and moisture.

Ondansetron may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - QT‑prolonging agents: co‑administration with drugs such as quinidine, amiodarone, or certain antipsychotics can increase arrhythmia risk. - Serotonergic agents: concurrent use with MAO‑inhibitors, SSRIs, or tramadol may precip 

Moderate  g  g  ewline

g

t